NOVOCURE LTD (NVCR) Stock Fundamental Analysis

NASDAQ:NVCR • JE00BYSS4X48

14.62 USD
+2.88 (+24.53%)
Last: Feb 25, 2026, 11:55 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, NVCR scores 2 out of 10 in our fundamental rating. NVCR was compared to 185 industry peers in the Health Care Equipment & Supplies industry. NVCR has a bad profitability rating. Also its financial health evaluation is rather negative. NVCR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • NVCR had negative earnings in the past year.
  • NVCR had a negative operating cash flow in the past year.
  • In the past 5 years NVCR reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: NVCR reported negative operating cash flow in multiple years.
NVCR Yearly Net Income VS EBIT VS OCF VS FCFNVCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

  • NVCR has a Return On Assets of -13.05%. This is comparable to the rest of the industry: NVCR outperforms 58.92% of its industry peers.
  • Looking at the Return On Equity, with a value of -52.05%, NVCR is in line with its industry, outperforming 50.81% of the companies in the same industry.
Industry RankSector Rank
ROA -13.05%
ROE -52.05%
ROIC N/A
ROA(3y)-13.14%
ROA(5y)-8.53%
ROE(3y)-41.63%
ROE(5y)-26.99%
ROIC(3y)N/A
ROIC(5y)N/A
NVCR Yearly ROA, ROE, ROICNVCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

  • Looking at the Gross Margin, with a value of 75.57%, NVCR belongs to the top of the industry, outperforming 87.03% of the companies in the same industry.
  • NVCR's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for NVCR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5Y0.68%
NVCR Yearly Profit, Operating, Gross MarginsNVCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • NVCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NVCR has been increased compared to 1 year ago.
  • Compared to 5 years ago, NVCR has more shares outstanding
  • NVCR has a worse debt/assets ratio than last year.
NVCR Yearly Shares OutstandingNVCR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
NVCR Yearly Total Debt VS Total AssetsNVCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of -0.10, we must say that NVCR is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -0.10, NVCR perfoms like the industry average, outperforming 45.95% of the companies in the same industry.
  • A Debt/Equity ratio of 2.21 is on the high side and indicates that NVCR has dependencies on debt financing.
  • NVCR has a worse Debt to Equity ratio (2.21) than 83.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.21
Debt/FCF N/A
Altman-Z -0.1
ROIC/WACCN/A
WACC8.5%
NVCR Yearly LT Debt VS Equity VS FCFNVCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • NVCR has a Current Ratio of 1.55. This is a normal value and indicates that NVCR is financially healthy and should not expect problems in meeting its short term obligations.
  • NVCR's Current ratio of 1.55 is on the low side compared to the rest of the industry. NVCR is outperformed by 74.05% of its industry peers.
  • A Quick Ratio of 1.50 indicates that NVCR should not have too much problems paying its short term obligations.
  • NVCR has a Quick ratio (1.50) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.55
Quick Ratio 1.5
NVCR Yearly Current Assets VS Current LiabilitesNVCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • NVCR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.00%.
  • Looking at the last year, NVCR shows a quite strong growth in Revenue. The Revenue has grown by 11.17% in the last year.
  • The Revenue has been growing by 11.49% on average over the past years. This is quite good.
EPS 1Y (TTM)-15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.86%
Revenue 1Y (TTM)11.17%
Revenue growth 3Y4.2%
Revenue growth 5Y11.49%
Sales Q2Q%7.81%

3.2 Future

  • Based on estimates for the next years, NVCR will show a very strong growth in Earnings Per Share. The EPS will grow by 21.91% on average per year.
  • Based on estimates for the next years, NVCR will show a quite strong growth in Revenue. The Revenue will grow by 18.14% on average per year.
EPS Next Y8.74%
EPS Next 2Y0.77%
EPS Next 3Y8.15%
EPS Next 5Y21.91%
Revenue Next Year9.59%
Revenue Next 2Y7.45%
Revenue Next 3Y8.34%
Revenue Next 5Y18.14%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NVCR Yearly Revenue VS EstimatesNVCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
NVCR Yearly EPS VS EstimatesNVCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2 -2 3

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NVCR. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVCR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NVCR Price Earnings VS Forward Price EarningsNVCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVCR Per share dataNVCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.77%
EPS Next 3Y8.15%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for NVCR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NOVOCURE LTD

NASDAQ:NVCR (2/25/2026, 11:55:57 AM)

14.62

+2.88 (+24.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-30
Earnings (Next)02-26
Inst Owners83.68%
Inst Owner Change6.84%
Ins Owners2.76%
Ins Owner Change0.22%
Market Cap1.64B
Revenue(TTM)642.27M
Net Income(TTM)-177.65M
Analysts81.54
Price Target24.55 (67.92%)
Short Float %7.91%
Short Ratio4.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.64%
Min EPS beat(2)8.12%
Max EPS beat(2)23.15%
EPS beat(4)3
Avg EPS beat(4)-2.03%
Min EPS beat(4)-73.92%
Max EPS beat(4)34.54%
EPS beat(8)7
Avg EPS beat(8)8.46%
EPS beat(12)8
Avg EPS beat(12)0.73%
EPS beat(16)10
Avg EPS beat(16)-6.5%
Revenue beat(2)2
Avg Revenue beat(2)1.97%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.98%
Revenue beat(4)4
Avg Revenue beat(4)1.94%
Min Revenue beat(4)0.18%
Max Revenue beat(4)3.65%
Revenue beat(8)7
Avg Revenue beat(8)3.15%
Revenue beat(12)7
Avg Revenue beat(12)1.16%
Revenue beat(16)9
Avg Revenue beat(16)0.67%
PT rev (1m)-1.75%
PT rev (3m)-2.5%
EPS NQ rev (1m)-1.41%
EPS NQ rev (3m)-4.84%
EPS NY rev (1m)0%
EPS NY rev (3m)0.54%
Revenue NQ rev (1m)-0.48%
Revenue NQ rev (3m)2.62%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.55
P/FCF N/A
P/OCF N/A
P/B 4.8
P/tB 4.8
EV/EBITDA N/A
EPS(TTM)-1.61
EYN/A
EPS(NY)-1.54
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS5.74
BVpS3.05
TBVpS3.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.05%
ROE -52.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.57%
FCFM N/A
ROA(3y)-13.14%
ROA(5y)-8.53%
ROE(3y)-41.63%
ROE(5y)-26.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5Y0.68%
F-Score2
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 2.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 226.76%
Cap/Sales 4.78%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.55
Quick Ratio 1.5
Altman-Z -0.1
F-Score2
WACC8.5%
ROIC/WACCN/A
Cap/Depr(3y)276.52%
Cap/Depr(5y)245.8%
Cap/Sales(3y)5.46%
Cap/Sales(5y)4.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.86%
EPS Next Y8.74%
EPS Next 2Y0.77%
EPS Next 3Y8.15%
EPS Next 5Y21.91%
Revenue 1Y (TTM)11.17%
Revenue growth 3Y4.2%
Revenue growth 5Y11.49%
Sales Q2Q%7.81%
Revenue Next Year9.59%
Revenue Next 2Y7.45%
Revenue Next 3Y8.34%
Revenue Next 5Y18.14%
EBIT growth 1Y-10.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.92%
EBIT Next 3Y27.38%
EBIT Next 5Y42.57%
FCF growth 1Y26.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.83%
OCF growth 3YN/A
OCF growth 5YN/A

NOVOCURE LTD / NVCR FAQ

What is the fundamental rating for NVCR stock?

ChartMill assigns a fundamental rating of 2 / 10 to NVCR.


What is the valuation status of NOVOCURE LTD (NVCR) stock?

ChartMill assigns a valuation rating of 0 / 10 to NOVOCURE LTD (NVCR). This can be considered as Overvalued.


Can you provide the profitability details for NOVOCURE LTD?

NOVOCURE LTD (NVCR) has a profitability rating of 2 / 10.